Nursing home residents and people over 80 will be next on the list.
The government has made these two groups a top priority for the immunization program.
The vaccine developed by Pfizer and its German partner BioNTech is expected to obtain regulatory approval in the coming days.
Coronavirus vaccine to be deployed in 10 days as British hospitals are put on alert
Boris Johnson hopes vaccination program rolls out before Christmas
On Monday, the UK’s medicines regulator said it would make a decision on the Pfizer vaccine “as soon as possible”.
The Medicines and Health Products Regulatory Agency made the announcement after receiving additional data on the injection.
In a statement, the executive agency of the Ministry of Health and Social Affairs said a thorough assessment of the data would be carried out.
June Raine, chief executive of the agency, said: “It is our job now to rigorously assess this data and the submitted evidence on the safety, quality and efficacy of the vaccine.
NHS workers will be given priority treatment in the jab queue
“As we received this data during an ongoing review, we have already started our analysis and will endeavor to reach a decision as soon as possible, without compromising the thoroughness of our review. ”
Earlier this month, Pfizer became the first drugmaker to publish the first analyzes of its Phase 3 trials involving 43,000 people worldwide.
The results were hailed around the world as a breakthrough in the race for a COVID jab.
The vaccine was found to be over 90% effective in preventing the virus in participants.
The military should play a key role in the deployment of the vaccination program
But further analysis of the jab released last week showed 95% effectiveness.
A former director of the Department of Health on Friday said ministers would face “tough choices” if the COVID vaccination vaccine produced by AstraZeneca and the University of Oxford proves to be less effective than other candidates.
Professor David Salisbury said the government should think “very carefully” about their handling of the vaccine if it was less effective than other injections such as those from Pfizer / BioNTech and Moderna.
The AstraZeneca / Oxford vaccine is currently being evaluated by the Medicines and Health Products Regulatory Agency for use in the UK.
Data from two arms from its phase three trial, announced last week, yielded a combined efficacy of 70%.
Half a dose followed by a full dose was 90% effective, but the figure was 62% for people who received two full doses.
The 90% result was based on a regimen given to 2,741 people, while the two-dose arm of the trial involved 8,895 people.
AstraZeneca has announced that it will conduct another global clinical trial to assess the 90% regimen, which it says was the result of a dosing error.
Pfizer developed the jab with its German partner BioNTech
Professor Salisbury told BBC Radio 4’s Today show: ‘I think this has to be counted and it may not be possible to do it with the number of patients who have been recruited so far. .
“If this vaccine came to 90% and it is a cheaper vaccine and requires a much less rigorous cold chain (storage) than RNA vaccines (from Pfizer and Moderna), then this would be a great result. ”
Speaking at a press conference in Downing Street on Tuesday, Mr Johnson suggested that the ‘vast majority’ of people from groups deemed most vulnerable to coronavirus could be trapped before Easter.
The Prime Minister said that achieving this goal “would bring a very substantial change to our current situation”.
The UK recorded 16,022 new coronavirus infections and 521 deaths within 28 days of testing positive on Friday.